Related Experiment Video

Updated: May 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

[Clinical application of fluorocholine positron emission tomography in relapsed prostate cancer]

M Oelstrom, R Núñez, P Sanchez

    Actas Urologicas Espanolas
    |June 20, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Experiment Videos

    Last Updated: May 21, 2026

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
    06:54

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

    Published on: September 3, 2013

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Concept Videos

    Positron Emission Tomography01:29

    Positron Emission Tomography

    Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
    One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
    Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

    Imaging Studies II: Positron Emission Tomography and Scintigraphy

    Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
    Fundamental Principles of PET

    Articles linked to this work by shared authors, journal, and citation graph.

    First ^{94}Nb(n,γ) Measurement: Constraining the Nucleosynthetic Origin of ^{94}Mo in Presolar Grains.

    Physical review letters·2026

    Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.

    ESMO real world data and digital oncology·2026

    Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

    The oncologist·2026

    Low thermal inertia of carbonaceous asteroid Bennu driven by cracks observed in returned samples.

    Nature communications·2026

    EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain.

    ESMO real world data and digital oncology·2026

    Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025

    The role of stone composition in determining outcomes after percutaneous nephrolithotomy.

    Actas urologicas espanolas·2026

    Predicting success after retrograde intrarenal surgery for 10-20 mm renal stones: A comparison of scoring systems.

    Actas urologicas espanolas·2026

    Urinary incontinence after treatment for localized prostate cancer: A systematic review and meta-analysis.

    Actas urologicas espanolas·2026

    Imaging modalities in advanced prostate cancer: Interim analysis of the Spanish cohort of the RING registry.

    Actas urologicas espanolas·2026

    Effectiveness and safety of hormonal doublet therapy in metastatic hormone-sensitive prostate cancer: A multicenter real-world study.

    Actas urologicas espanolas·2026

    External validation of six scoring systems for predicting retrograde intrarenal surgery outcomes in obese patients.

    Actas urologicas espanolas·2026

    Evolving person-focused cancer care: the multifaceted benefits of electronic PRO integration and radiation therapist-led follow-up in radiotherapy.

    Technical innovations & patient support in radiation oncology·2026

    C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.

    Precision radiation oncology·2026

    Radiotherapy for postoperative groin lymphatic fistulas: A systematic review of clinical outcomes and treatment planning.

    Clinical and translational radiation oncology·2026

    Re-evaluating the α/β ratio in 2026: A systematic review and quantitative reappraisal in the era of molecular radiobiology.

    Medical dosimetry : official journal of the American Association of Medical Dosimetrists·2026

    Clinical and Treatment Factors associated with Lymphopenia after Palliative Radiation Therapy in Cancer Patients.

    International journal of radiation oncology, biology, physics·2026

    Bayesian personalized dose constraints in selecting patients with non-small cell lung cancer for cardiac risk-adaptive treatment.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us